3D Signatures (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) appointed Dr. Kevin Little, a leading biomedical scientist and corporate executive, as its new chief scientific officer, effective immediately.  

John Calcagnini has joined Stout Risius Ross as managing director in the investment banking group’s healthcare industry practice.

3D Signatures (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) has appointed Harry Glorikian to its business advisory board.

BioTime (NYSE MKT:BTX) has appointed Stephana Patton as general counsel, a newly created position. Reporting in her new role to Adi Mohanty, co-CEO, Dr. Patton will oversee all legal matters at the company.

Richard Glickman, founder and chairman of Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP), was named to the added post of CEO. The board also accepted the resignation of Charles Rowland as CEO and an executive member of...

Kenneth Galbraith, an accomplished life sciences industry veteran, has been appointed a director of Profound Medical (TSX-V:PRN). Mr. Galbraith has over 25 years of experience as an executive, director, investor and...

Steven Plymale, president and COO of Profound Medical (TSX-V:PRN), has been appointed an independent director of XOR-Labs, a spinoff from Toronto General Hospital at University Health Network, the world's leading center...

John Chambers has joined H.C. Wainwright as president and head of investment banking. Mr. Chambers joins HCW from Roth Capital Partners where he was vice chairman and head of healthcare investment banking. In his 28...

Roth Capital Partners has appointed Michael Margolis as head of healthcare investment banking. Mr. Margolis has been a managing director at the firm since 2010.

3D Signatures (TSX-V:DXD) has appointed Joost van der Mark as its chief business officer, effective Jan. 6.

Joseph Pantginis has joined Rodman & Renshaw in equity research as a managing director covering biotechnology.

Titan Pharmaceuticals (NASDAQ:TTNP), in a move to boost its product development and commercialization experience in the U.S., Europe and Asia, named Scott Smith and Dr. Rajinder Kumar to its board.

Cantor Fitzgerald has expanded its healthcare equity research team with the addition of Bill Tanner as a senior research analyst covering biotechnology and Steven Halper as a senior research analyst covering healthcare...

Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) appointed Lorin Jeffry Randall to its board and chairman of the audit committee.

3D Signatures (TSX-V:DXD) named Helen Stevenson to the board and Ian Smith, who is stepping down from the board, to the clinical and scientific advisory board (CSAB).

3D Signatures (TSX-V:DXD) has appointed Nigel Terrett to 3DS's business advisory board to provide the company with strategic insight and guidance related to commercial lab partnerships and information technology...

Jeff Sacher has joined Aegis Capital to lead the firm's global healthcare effort as a managing director.Previously, Mr. Sacher was a senior banker at Goldman Sachs, Needham and Brean Capital. In addition, he has served...

Microbix Biosystems (TSX:MBX) appointed Jim Currie as CFO, succeeding Charles Wallace, who is retiring at the end of the year.Mr. Currie was most recently CFO of SMTC, a global electronics manufacturing services company...

3D Signatures (TSX-V:DXD) has appointed Jason Flowerday as CEO. He succeeds Ferenc Somogyvari, who will remain on the board."Mr. Flowerday is a highly respected biotech entrepreneur with more than 20 years of executive...

Stereotaxis (NASDAQ:STXS) has signed definitive agreements for multiple transactions that significantly strengthen its financial position and help accelerate and enhance its strategic market growth initiatives.The...

pSivida (NASDAQ:PSDV) has appointed Nancy Lurker as president, CEO and a member of the board, succeeding Paul Ashton, who has resigned to pursue other interests.Ms. Lurker, a seasoned healthcare executive, brings strong...